Related Experiment Video
Updated: Apr 17, 2026

How to Obtain Reliable Visual Event-related Potentials in Newborns
Published on: October 24, 2019
Longitudinal polysomnographic findings in infantile Pompe disease
Sujay Kansagra1, Stephanie Austin, Stephanie DeArmey
1Division of Pediatric Neurology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina.
Insights
Enzyme replacement therapy (ERT) shows stability in sleep-disordered breathing for infantile Pompe disease patients. This treatment may improve obstructive sleep apnea and central sleep apnea in children with this rare metabolic disorder.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Infantile Pompe disease is a rare metabolic disorder caused by acid α-glucosidase deficiency, leading to glycogen accumulation.
- This deficiency causes multisystem dysfunction, notably neuromuscular weakness and sleep-disordered breathing.
- Enzyme replacement therapy (ERT) has altered the natural history, enabling longer survival.
Purpose of the Study:
- To analyze the longitudinal impact of ERT on sleep-disordered breathing in infantile Pompe disease.
- To assess changes in hypoventilation, obstructive sleep apnea (OSA), and central sleep apnea (CSA) in patients on ERT.
Main Methods:
- Retrospective analysis of nocturnal polysomnography data.
- Inclusion of 10 patients with infantile-onset Pompe disease on ERT for a mean of 34.9 months.
Main Results:
- Sleep-disordered breathing parameters remained relatively stable over time.
- A trend towards improvement was observed in both obstructive sleep apnea and central sleep apnea.
- No significant worsening of hypoventilation was noted during ERT.
Conclusions:
- ERT appears to stabilize, and potentially improve, sleep-disordered breathing in infantile Pompe disease.
- This suggests ERT may play a beneficial role in managing respiratory complications.
- Further research is warranted to confirm these findings and optimize treatment strategies.
Abstract:
Infantile Pompe disease is a rare, metabolic disorder due to deficiency of the enzyme acid α-glucosidase that degrades lysosomal glycogen. The deficiency leads to multisystem dysfunction. Neuromuscular weakness due to metabolic myopathy is present, which predisposes children to sleep-disordered breathing. With the advent of enzyme replacement therapy (ERT), children are living longer, and there is a new natural history that is emerging. In a prior paper on our cohort of infantile Pompe disease patients, we reported a high incidence of both hypoventilation and obstructive sleep apnea (OSA). In this retrospective study, we analyzed longitudinal nocturnal polysomnography results from 10 patients with infantile-onset Pompe disease, all of which were on enzyme replacement therapy for a mean of 34.9 months at the time of follow-up study. Patients demonstrated relative stability in sleep disordered breathing, with a trend towards improvement in both OSA and central sleep apnea. ERT may help in the treatment of sleep apnea in this cohort.
Related Concept Videos
REM Sleep Behavior Disorder
RBD is significantly associated with...
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Stages of Sleep
Before sleep begins, in wakefulness, the brain exhibits primarily beta waves, which are high in frequency and low in amplitude, indicating alertness...
Sleep Apnea
The condition is more prevalent among...

